JP2006524186A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006524186A5 JP2006524186A5 JP2005508461A JP2005508461A JP2006524186A5 JP 2006524186 A5 JP2006524186 A5 JP 2006524186A5 JP 2005508461 A JP2005508461 A JP 2005508461A JP 2005508461 A JP2005508461 A JP 2005508461A JP 2006524186 A5 JP2006524186 A5 JP 2006524186A5
- Authority
- JP
- Japan
- Prior art keywords
- alkynyl
- alkenyl
- branched
- alkyl
- linear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 39
- 125000003342 alkenyl group Chemical group 0.000 claims 38
- 125000000304 alkynyl group Chemical group 0.000 claims 38
- 239000000203 mixture Substances 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 230000000340 anti-metabolite Effects 0.000 claims 7
- 229940100197 antimetabolite Drugs 0.000 claims 7
- 239000002256 antimetabolite Substances 0.000 claims 7
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 claims 5
- -1 nitro, cyano, amino Chemical group 0.000 claims 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 4
- 229960000390 fludarabine Drugs 0.000 claims 4
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 229960000684 cytarabine Drugs 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 229960000485 methotrexate Drugs 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000006413 ring segment Chemical group 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical group NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 206010034038 Parotitis Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 229960001330 hydroxycarbamide Drugs 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43155502P | 2002-12-06 | 2002-12-06 | |
| US60/431,555 | 2002-12-06 | ||
| US49626103P | 2003-08-19 | 2003-08-19 | |
| US60/496,261 | 2003-08-19 | ||
| PCT/US2003/038523 WO2004052349A2 (en) | 2002-12-06 | 2003-12-04 | Compositions comprising a combination of diphenyl ura impdh inhibitors and apoptosis-inducing anti-cancer agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006524186A JP2006524186A (ja) | 2006-10-26 |
| JP2006524186A5 true JP2006524186A5 (https=) | 2007-01-25 |
| JP4789621B2 JP4789621B2 (ja) | 2011-10-12 |
Family
ID=32511581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005508461A Expired - Fee Related JP4789621B2 (ja) | 2002-12-06 | 2003-12-04 | ジフェニルＵｒａＩＭＰＤＨインヒビターおよびアポトーシス誘導性抗癌剤を含む組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7943593B2 (https=) |
| EP (1) | EP1575579B1 (https=) |
| JP (1) | JP4789621B2 (https=) |
| AT (1) | ATE424198T1 (https=) |
| AU (1) | AU2003298868B2 (https=) |
| CA (1) | CA2510006C (https=) |
| DE (1) | DE60326488D1 (https=) |
| WO (1) | WO2004052349A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ564252A (en) | 2005-05-26 | 2011-04-29 | Vertex Pharma | Polymorphic forms of (s)-1-cyanobutan-2-yl (s)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) phenyl) ethylcarbamate |
| CN119970617A (zh) * | 2019-04-05 | 2025-05-13 | 普罗林科斯有限责任公司 | 改良偶联接头 |
| JP2022136035A (ja) * | 2021-03-04 | 2022-09-15 | 国立大学法人東京農工大学 | 化合物、該化合物を用いた金属ナノ粒子複合体、及び標的分子の検出方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4210745A (en) * | 1978-01-04 | 1980-07-01 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoroadenine |
| US4357324A (en) * | 1981-02-24 | 1982-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine |
| US5807876A (en) * | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| TW409125B (en) * | 1996-04-22 | 2000-10-21 | Novartis Ag | Antivirally active heterocyclic azahexane derivatives |
| HUP0004421A3 (en) * | 1996-04-23 | 2002-10-28 | Vertex Pharmaceuticals Inc Cam | Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme |
| AP1498A (en) * | 1999-03-19 | 2005-11-21 | Vertex Pharma | Inhibitors of impdh enzyme. |
-
2003
- 2003-12-04 US US10/728,114 patent/US7943593B2/en not_active Expired - Fee Related
- 2003-12-04 JP JP2005508461A patent/JP4789621B2/ja not_active Expired - Fee Related
- 2003-12-04 WO PCT/US2003/038523 patent/WO2004052349A2/en not_active Ceased
- 2003-12-04 AU AU2003298868A patent/AU2003298868B2/en not_active Ceased
- 2003-12-04 DE DE60326488T patent/DE60326488D1/de not_active Expired - Lifetime
- 2003-12-04 AT AT03796628T patent/ATE424198T1/de not_active IP Right Cessation
- 2003-12-04 CA CA2510006A patent/CA2510006C/en not_active Expired - Fee Related
- 2003-12-04 EP EP03796628A patent/EP1575579B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6905609B2 (ja) | 癌の処置のためのウリジンのジオキソラン類似体 | |
| JP2005526857A5 (https=) | ||
| ES2247131T3 (es) | Procedimiento de compuestos de azol solubles en agua. | |
| JP2004500352A5 (https=) | ||
| JP2006505543A5 (https=) | ||
| JP2009504772A5 (https=) | ||
| RU2002118327A (ru) | Фосфонатные соединения | |
| WO2011017521A4 (en) | Bicyclic cyclohexose nucleic acid analogs | |
| JP2006514114A5 (https=) | ||
| JP2022533069A5 (https=) | ||
| JP2005525991A5 (https=) | ||
| JP2010535706A5 (https=) | ||
| JP2019534865A5 (https=) | ||
| JP2006524186A5 (https=) | ||
| JP2001513567A5 (https=) | ||
| CA2576191A1 (en) | T type calcium channel inhibitors | |
| JP2008133274A5 (https=) | ||
| JP2023533616A5 (https=) | ||
| TW200505438A (en) | Method of treating cancer with azaspirane compositions | |
| JP2008502673A5 (https=) | ||
| RU2005101201A (ru) | Аминоацетонитрилбные производные, пригодные для борьбы с паразитами | |
| MXPA95000363A (en) | Monohiddrate of (e) -2'-desoxy-2'- (fluorometilen) citid | |
| AU1553295A (en) | Monohydrate of (e)-2'-deoxy-2'-(fluoromethylene)cytidine | |
| BRPI0514718A (pt) | método para a preparação de 2'-desoxi-2', 2'-diflúor-citidina | |
| HUT76857A (en) | Intermediates for dinucleotide and oligonucleotide analogues and process for producing them |